{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:13:19Z","timestamp":1789071199183,"version":"build-2803163510"},"reference-count":39,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T00:00:00Z","timestamp":1623110400000},"content-version":"unspecified","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Radio-T\u00e9l\u00e9vision belge de la Communaut\u00e9 fran\u00e7aise","award":["CAP48 program"],"award-info":[{"award-number":["CAP48 program"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>In the management of juvenile idiopathic arthritis (JIA), there is a lack of diagnostic and prognostic biomarkers. This study assesses the use of serum calprotectin (sCal) as a marker to monitor disease activity, and as a classification and prognosis tool of response to treatment or risk of flares in patients with JIA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eighty-one patients with JIA from the CAP48 multicentric cohort were included in this study, as well as 11 non-paediatric healthy controls. An ELISA method was used to quantify sCal with a commercial kit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients with an active disease compared with healthy controls and with patients with inactive disease showed an eightfold and a twofold increased level of sCal, respectively. sCal was found to be correlated with the C-reactive protein (CRP) and even more strongly with the erythrocyte sedimentation rate. Evolution of DAS28 scores correlated well with evolution of sCal, as opposed to evolution of CRP. With regard to CRP, sCal could differentiate forms with active oligoarthritis from polyarthritis and systemic forms. However, sCal brought an added value compared with the CRP as a prognosis marker. Indeed, patients with active disease and reaching minimal disease activity (according to Juvenile Arthritis Disease Activity Score) at 6 months following the test had higher sCal levels, while patients with inactive disease had higher sCal levels if a flare was observed up to 3\u20139 months following the test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study confirms the potential uses of sCal as a biomarker in the diagnosis and follow-up of JIA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2021-001646","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T10:11:18Z","timestamp":1668679878000},"page":"e001646","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":20,"title":["Serum calprotectin (S100A8\/A9): a promising biomarker in diagnosis and follow-up in different subgroups of juvenile idiopathic arthritis"],"prefix":"10.1136","volume":"7","clinical-trial-number":[{"clinical-trial-number":"nct69963079","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6065-2970","authenticated-orcid":false,"given":"C\u00e9line","family":"La","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phu Quoc","family":"L\u00ea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Ferster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Goffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Spruyt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Lauwerys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7156-2356","authenticated-orcid":false,"given":"Patrick","family":"Durez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"Boulanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Sokolova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Rasschaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Badot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,6,9]]},"reference":[{"key":"2022111503194959000_7.2.e001646.1","first-page":"390","article-title":"International League of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"2022111503194959000_7.2.e001646.2","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","article-title":"Juvenile idiopathic arthritis","volume":"369","author":"Ravelli","year":"2007","journal-title":"The Lancet"},{"key":"2022111503194959000_7.2.e001646.3","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/S0140-6736(11)60244-4","article-title":"Juvenile idiopathic arthritis","volume":"377","author":"Prakken","year":"2011","journal-title":"The Lancet"},{"key":"2022111503194959000_7.2.e001646.4","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0306170"},{"key":"2022111503194959000_7.2.e001646.5","doi-asserted-by":"crossref","first-page":"e678","DOI":"10.1016\/j.crohns.2013.06.008","article-title":"Serum calprotectin as a biomarker for Crohn\u2019s disease","volume":"7","author":"Meuwis","year":"2013","journal-title":"Journal of Crohn's and Colitis"},{"key":"2022111503194959000_7.2.e001646.6","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201407-1365LE"},{"key":"2022111503194959000_7.2.e001646.7","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.diagmicrobio.2018.10.006","article-title":"Calprotectin and calgranulin C serum levels in bacterial sepsis","volume":"93","author":"Bart\u00e1kov\u00e1","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2022111503194959000_7.2.e001646.8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13075-020-02190-3","article-title":"Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis","volume":"22","author":"Jarlborg","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2022111503194959000_7.2.e001646.9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s13075-018-1764-z","article-title":"Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study","volume":"20","author":"Inciarte-Mundo","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2022111503194959000_7.2.e001646.10","doi-asserted-by":"crossref","unstructured":"Tweehuysen L , den Broeder N , van Herwaarden N . Predictive value of serum calprotectin (S100A8\/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis. RMD Open 2018;4:e000654.","DOI":"10.1136\/rmdopen-2018-000654"},{"key":"2022111503194959000_7.2.e001646.11","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001220"},{"key":"2022111503194959000_7.2.e001646.12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/0961203316655208","article-title":"Pro-Inflammatory S100 proteins are associated with glomerulonephritis and anti-dsDNA antibodies in systemic lupus erythematosus","volume":"26","author":"Tyd\u00e9n","year":"2017","journal-title":"Lupus"},{"key":"2022111503194959000_7.2.e001646.13","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.cell.2020.08.002","article-title":"Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19","volume":"182","author":"Silvin","year":"2020","journal-title":"Cell"},{"key":"2022111503194959000_7.2.e001646.14","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200003)43:3<628::AID-ANR20>3.0.CO;2-X"},{"key":"2022111503194959000_7.2.e001646.15","doi-asserted-by":"publisher","DOI":"10.1002\/art.11177"},{"key":"2022111503194959000_7.2.e001646.16","unstructured":"Foell D , Park C , Ziegler L . Successful Validation of a Rapid Point-of-care Test for Serum Calprotectin (MRP8\/14) as Biomarker in Juvenile Idiopathic Arthritis [abstract]. Arthritis Rheumatol Hoboken NJ 2020;72 https:\/\/acrabstracts.org\/abstract\/successful-validation-of-a-rapid-point-of-care-test-for-serum-calprotectin-mrp8-14-as-biomarker-in-juvenile-idiopathic-arthritis\/"},{"key":"2022111503194959000_7.2.e001646.17","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/acr.22248","article-title":"Validation of relapse risk biomarkers for routine use in patients with juvenile idiopathic arthritis","volume":"66","author":"Rothmund","year":"2014","journal-title":"Arthritis Care Res"},{"key":"2022111503194959000_7.2.e001646.18","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.005686"},{"key":"2022111503194959000_7.2.e001646.19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201329"},{"key":"2022111503194959000_7.2.e001646.20","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s13075-015-0723-1","article-title":"MRP8\/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis","volume":"17","author":"Anink","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2022111503194959000_7.2.e001646.21","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.084459"},{"key":"2022111503194959000_7.2.e001646.22","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20205"},{"key":"2022111503194959000_7.2.e001646.23","doi-asserted-by":"publisher","DOI":"10.1002\/art.24516"},{"key":"2022111503194959000_7.2.e001646.24","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev353"},{"key":"2022111503194959000_7.2.e001646.25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204186"},{"key":"2022111503194959000_7.2.e001646.26","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20497"},{"key":"2022111503194959000_7.2.e001646.27","doi-asserted-by":"publisher","DOI":"10.1002\/art.34373"},{"key":"2022111503194959000_7.2.e001646.28","first-page":"1058","article-title":"Preliminary definition of disease flare in juvenile rheumatoid arthritis","volume":"29","author":"Brunner","year":"2002","journal-title":"J Rheumatol"},{"key":"2022111503194959000_7.2.e001646.29","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200108)44:8<1768::AID-ART312>3.0.CO;2-Q"},{"key":"2022111503194959000_7.2.e001646.30","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200598"},{"key":"2022111503194959000_7.2.e001646.31","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket152"},{"key":"2022111503194959000_7.2.e001646.32","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/art.41062","article-title":"A neutrophil activation biomarker panel in prognosis and monitoring of patients with rheumatoid arthritis","volume":"72","author":"Bach","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2022111503194959000_7.2.e001646.33","article-title":"Scavenger receptor-A is a biomarker and effector of rheumatoid arthritis: a large-scale multicenter study","volume":"11","author":"Hu","year":"2020","journal-title":"Nat Commun"},{"key":"2022111503194959000_7.2.e001646.34","doi-asserted-by":"crossref","unstructured":"Ciregia F , Baiwir D , Cobraiville G , et al . Glycosylation deficiency of lipopolysaccharide-binding protein and corticosteroid-binding globulin associated with activity and response to treatment for rheumatoid arthritis. J Transl Med 2020;18:8. doi:10.1186\/s12967-019-02188-9","DOI":"10.1186\/s12967-019-02188-9"},{"key":"2022111503194959000_7.2.e001646.35","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.375"},{"key":"2022111503194959000_7.2.e001646.36","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/art.40727","article-title":"Serum S100A8\/A9 and S100A12 levels in children with polyarticular forms of juvenile idiopathic arthritis: relationship to maintenance of clinically inactive disease during anti-tumor necrosis factor therapy and occurrence of disease flare after discontinuation of therapy","volume":"71","author":"Hinze","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2022111503194959000_7.2.e001646.37","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1093\/rheumatology\/kez590","article-title":"MRP8\/14 and neutrophil elastase for predicting treatment response and occurrence of flare in patients with juvenile idiopathic arthritis","volume":"59","author":"Barendregt","year":"2020","journal-title":"Rheumatology"},{"key":"2022111503194959000_7.2.e001646.38","doi-asserted-by":"publisher","DOI":"10.1002\/art.24349"},{"key":"2022111503194959000_7.2.e001646.39","first-page":"4916","article-title":"IFN-Gamma and TNF regulate macrophage expression of the chemotactic S100 protein S100A8","volume":"1950","author":"Xu","year":"2000","journal-title":"J Immunol Baltim Md"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2021-001646","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T04:36:52Z","timestamp":1701405412000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2021-001646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,6,9]]},"published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1136\/rmdopen-2021-001646"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2021-001646","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]}}}